ST316
Phase 1Small molecule
ST316 is one of 20 small molecule programs targeting Colon Cancer. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Colon Cancer
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Eloxatin
TevaPhase 3
Camptosar
PfizerPhase 3
Adrucil
EElorac, Inc.
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Erbitux
IImclone
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
Acetylsalicylic Acid
BayerPhase 3
Libtayo
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Familial Adenomatous Polyposis (FAP)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ST316. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSapience Therapeutics